EA033437B1 - Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний - Google Patents

Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний

Info

Publication number
EA033437B1
EA033437B1 EA201590845A EA201590845A EA033437B1 EA 033437 B1 EA033437 B1 EA 033437B1 EA 201590845 A EA201590845 A EA 201590845A EA 201590845 A EA201590845 A EA 201590845A EA 033437 B1 EA033437 B1 EA 033437B1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
treating
autoimmune diseases
preventing inflammatory
present
Prior art date
Application number
EA201590845A
Other languages
English (en)
Other versions
EA201590845A1 (ru
EA033437B9 (ru
Inventor
Peter Sondermann
Meer Dominik Ter
Thomas Pohl
Reno Winter
Uwe Jacob
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of EA201590845A1 publication Critical patent/EA201590845A1/ru
Publication of EA033437B1 publication Critical patent/EA033437B1/ru
Publication of EA033437B9 publication Critical patent/EA033437B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Изобретение относится к нуклеиновой кислоте, кодирующей Fc-гамма-рецептор IIB (FcγRIIB) с аминокислотной последовательностью SEQ ID NO: 1, обладающий повышенной растворимостью в присутствии высоких концентраций сульфата аммония; к вектору, содержащему указанную нуклеиновую кислоту, и к клетке-хозяину, содержащей указанную нуклеиновую кислоту или указанный вектор. Настоящее изобретение также относится к рецептору FcγRIIB, полученному посредством экспрессии указанной нуклеиновой кислоты или указанного вектора в клетке-хозяине. В дополнение к этому настоящее изобретение охватывает фармацевтическую композицию для лечения или предупреждения воспалительных заболеваний и/или аутоиммунных заболеваний, содержащую заявленный рецептор. Кроме того, настоящее изобретение относится к фармацевтической композиции для лечения или предупреждения воспалительных заболеваний и/или аутоиммунных заболеваний, содержащей варианты рецептора FcγRIIB с последовательностями SEQ ID NO: 2, 3, 4 и 5.
EA201590845A 2012-10-30 2013-10-30 Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний EA033437B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Publications (3)

Publication Number Publication Date
EA201590845A1 EA201590845A1 (ru) 2015-08-31
EA033437B1 true EA033437B1 (ru) 2019-10-31
EA033437B9 EA033437B9 (ru) 2020-03-19

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590845A EA033437B9 (ru) 2012-10-30 2013-10-30 Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний

Country Status (28)

Country Link
US (1) US10028998B2 (ru)
EP (1) EP2914624B1 (ru)
JP (2) JP6423351B2 (ru)
KR (1) KR102170674B1 (ru)
CN (1) CN104918955B (ru)
AU (1) AU2013340831B2 (ru)
BR (1) BR112015008815A2 (ru)
CA (1) CA2887164C (ru)
CL (1) CL2015001127A1 (ru)
DK (1) DK2914624T3 (ru)
EA (1) EA033437B9 (ru)
ES (1) ES2628049T3 (ru)
HK (1) HK1209765A1 (ru)
HR (1) HRP20170894T1 (ru)
HU (1) HUE032786T2 (ru)
IL (1) IL238528A (ru)
IN (1) IN2015DN03206A (ru)
LT (1) LT2914624T (ru)
MX (1) MX359802B (ru)
MY (1) MY173686A (ru)
NZ (1) NZ706884A (ru)
PH (1) PH12015500771B1 (ru)
PL (1) PL2914624T3 (ru)
PT (1) PT2914624T (ru)
RS (1) RS56075B1 (ru)
SG (1) SG11201502749VA (ru)
SI (1) SI2914624T1 (ru)
WO (1) WO2014068012A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN105873600B (zh) * 2013-10-16 2019-11-05 苏伯利莫尔公司 用于自身免疫性大疱病治疗的可溶性Fcγ受体
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えＦｃγＲＩＩｂ
MX2020014212A (es) * 2018-06-25 2021-03-09 Basf Coatings Gmbh Metodo para producir un revestimiento optimizado y un revestimiento que se puede obtener mediante el uso de dicho metodo.
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043648A2 (de) * 2001-11-22 2003-05-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten
EP1870422A1 (en) * 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1709073B1 (en) 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
DE602006020333D1 (de) 2005-12-13 2011-04-07 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
US8658766B2 (en) 2008-06-27 2014-02-25 Zymogenetics, Inc. Soluble hybrid Fcγ receptors and related methods
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043648A2 (de) * 2001-11-22 2003-05-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten
EP1870422A1 (en) * 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction

Also Published As

Publication number Publication date
AU2013340831A1 (en) 2015-04-30
EA201590845A1 (ru) 2015-08-31
EP2914624B1 (en) 2017-03-15
WO2014068012A1 (en) 2014-05-08
CN104918955B (zh) 2018-10-09
IN2015DN03206A (ru) 2015-10-02
MY173686A (en) 2020-02-15
CA2887164A1 (en) 2014-05-08
NZ706884A (en) 2019-05-31
KR102170674B1 (ko) 2020-10-28
EP2914624A1 (en) 2015-09-09
MX359802B (es) 2018-10-10
IL238528A (en) 2017-07-31
SG11201502749VA (en) 2015-05-28
CL2015001127A1 (es) 2015-12-18
PL2914624T3 (pl) 2017-09-29
US20140120080A1 (en) 2014-05-01
PT2914624T (pt) 2017-06-07
IL238528A0 (en) 2015-06-30
US10028998B2 (en) 2018-07-24
LT2914624T (lt) 2017-06-26
DK2914624T3 (en) 2017-06-26
AU2013340831B2 (en) 2017-11-23
HRP20170894T1 (hr) 2017-09-08
RS56075B1 (sr) 2017-10-31
JP6423351B2 (ja) 2018-11-14
PH12015500771A1 (en) 2015-06-08
HUE032786T2 (en) 2017-10-30
ES2628049T3 (es) 2017-08-01
MX2015005266A (es) 2015-10-26
JP2016503289A (ja) 2016-02-04
EA033437B9 (ru) 2020-03-19
BR112015008815A2 (pt) 2017-11-21
CN104918955A (zh) 2015-09-16
PH12015500771B1 (en) 2015-06-08
SI2914624T1 (sl) 2017-07-31
KR20150122621A (ko) 2015-11-02
JP2018186833A (ja) 2018-11-29
CA2887164C (en) 2020-12-29
HK1209765A1 (en) 2016-04-08

Similar Documents

Publication Publication Date Title
EA033437B1 (ru) Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний
MX2020004578A (es) Composiciones de casz y metodos de uso.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
GB201206559D0 (en) Polypeptide
MX2015014464A (es) Vectores para terapia genica para tratar cardiomiopatía.
EA033399B1 (ru) Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение
EA201391394A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
IN2014CN04586A (ru)
NZ616989A (en) Therapeutic nuclease compositions and methods
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX369726B (es) Polipéptidos con actividad proteasa.
WO2014202622A3 (en) Rasamsonia gene and use thereof
IN2014CN01706A (ru)
PH12018500155A1 (en) Recombinant orf virus vector
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
IN2014DN09963A (ru)
SG195302A1 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2015014354A (es) Poliplexos.
WO2014202623A3 (en) Rasamsonia gene and use thereof

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM